Author:
Rios Patricia,Cardoso Roberta,Morra Deanna,Nincic Vera,Goodarzi Zahra,Farah Bechara,Harricharan Sharada,Morin Charles M.,Leech Judith,Straus Sharon E.,Tricco Andrea C.
Abstract
Abstract
Background
This review aimed to assess the existing evidence regarding the clinical effectiveness and safety of pharmacological and non-pharmacological interventions in adults with insomnia and identify where research or policy development is needed.
Methods
MEDLINE, Embase, PsycINFO, The Cochrane Library, and PubMed were searched from inception until June 14, 2017, along with relevant gray literature sites. Two reviewers independently screened titles/abstracts and full-text articles, and a single reviewer with an independent verifier completed charting, data abstraction, and quality appraisal.
Results
A total of 64 systematic reviews (35 with meta-analysis) were included after screening 5024 titles and abstracts and 525 full-text articles. Eight of the included reviews were rated as high quality using the Assessment of Multiple Systematic Reviews 2 (AMSTAR2) tool, and over half of the included articles (n = 40) were rated as low or critically low quality. Consistent evidence of effectiveness across multiple outcomes based on more than one high- or moderate quality review with meta-analysis was found for zolpidem, suvorexant, doxepin, melatonin, and cognitive behavioral therapy (CBT), and evidence of effectiveness across multiple outcomes based on one high-quality review with meta-analysis was found for temazepam, triazolam, zopiclone, trazodone, and behavioral interventions. These interventions were mostly evaluated in the short term (< 16 weeks), and there was very little harms data available for the pharmacological interventions making it difficult to evaluate their risk-benefit ratio.
Conclusions
Assuming non-pharmacological interventions are preferable from a safety perspective CBT can be considered an effective first-line therapy for adults with insomnia followed by other behavioral interventions. Short courses of pharmacological interventions can be supplements to CBT or behavioral therapy; however, no evidence regarding the appropriate duration of pharmacological therapy is available from these reviews.
Systematic review registration
PROSPERO CRD42017072527.
Funder
Drug Safety and Effectiveness Network, Canadian Institutes of Health Research
Tier 1, Canada Research Chair in Knowledge Synthesis
Tier 2, Canada Research Chair in Knowledge Synthesis
Ontario Ministry of Research, Innovation and Science
Mary Trimmer Chair in Geriatric Medicine
Publisher
Springer Science and Business Media LLC
Reference88 articles.
1. Morin CM, LeBlanc M, Belanger L, Ivers H, Merette C, Savard J. Prevalence of insomnia and its treatment in Canada. Can J Psychiatry. 2011;56(9):540–8.
2. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7–10.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5): American Psychiatric Pub; 2013.
4. Morin CM, Jarrin DC. Epidemiology of insomnia: prevalence, course, risk factors, and public health burden. Sleep Med Clin. 2013;8(3):281–97.
5. Committee on Sleep Medicine and Research BoHSP. Sleep disorders and sleep deprivation: an unmet public health problem. Washington (DC): National Academies Press; 2006. Available from: https://www.nap.edu/catalog/11617/sleep-disorders-and-sleep-deprivation-an-unmet-public-health-problem